Abstract
Attempts to achieve revascularization of coronary arteries blocked by atherosclerotic plaques are hampered by restenotic hyperproliferative response of the treated vessels. The uniform failure of clinical trials using systemic therapies to prevent restenosis has prompted development of methods for arterial drug delivery systems. This review describes technologies of polymeric-based, perivascular, and intraluminal drug and gene delivery systems. The critical assessment of controversies including drug and vehicle type, dose and release rate, and preclinical validation is reviewed.
| Original language | English |
|---|---|
| Pages (from-to) | 249-284 |
| Number of pages | 36 |
| Journal | Critical Reviews in Therapeutic Drug Carrier Systems |
| Volume | 17 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2000 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Controlled release
- Drug delivery systems
- Nanoparticles
- Polymeric-based drug delivery
- Restenosis
Fingerprint
Dive into the research topics of 'Drug delivery systems for the treatment of restenosis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver